AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20702657
Drug: Recombinant EBA‐175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (5, 20, 80, or 160 μg) administered at 0, 1, and 6 months
Trial: 20702657
Drug: Recombinant EBA‐175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (3 doses at any concentration)
Trial: 17717960
Drug: Ketamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0, 1, or 10 mmol/L)
Trial: 17717960
Drug: Glutamate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (0.2 mL, 1 mol/L)
Trial: 8580384
Drug: IL‐1 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1 alpha (0.03 g/kg as a 30 minute infusion daily for 5 days)
Trial: 8580384
Drug: IL‐6 (5-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐6 (5-day continuous infusion)
Trial: 31567579
Drug: Ketorolac with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac with opioid medication
Trial: 28513346
Drug: Psychoeducation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation and Problem Solving (PEPS) therapy
Trial: 19731968
Drug: Haloperidol 7-10
RxNorm normalized name: haloperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 7-10 mg/day
Trial: 17324745
Drug: hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25 mg)
Trial: 7979935
Drug: 20% benzocaine
RxNorm normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% benzocaine spray
Trial: 7979935
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (benzocaine and placebo)
Trial: 7979935
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic (benzocaine)
Trial: 2658886
Drug: Automated control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated control of sodium nitroprusside administration
Trial: 2658886
Drug: Manual control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual control of sodium nitroprusside administration
Trial: 31819387
Drug: Resveratrol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol + Curcumin (500 mg each daily)
Trial: 29088038
Drug: PAI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAI with liposomal bupivacaine, ketorolac, and epinephrine (PAI-L)
Trial: 18095965
Drug: Propofol-ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-ketamine (1 mg.kg(‐1) ketamine + 1.2 mg.kg(‐1) propofol)
Trial: 18095965
Drug: Propofol-fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-fentanyl (1 microg.kg(‐1) fentanyl + 1.2 mg.kg(‐1) propofol)
Trial: 8616947
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g, intravenous infusion, 60 minutes)
Trial: 8616947
Drug: PGE1 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (40 microgram, intravenous infusion, 60 minutes)
Trial: 8616947
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 mL 0.9% saline, intravenous infusion, 60 minutes)
Trial: 3907738
Drug: sobrerol 400
RxNorm normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sobrerol 400 mg day-1 for 14 days
Trial: 11246060
Drug: Negative or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative or neutral trial (MACH‐1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor)
Trial: 7978587
Drug: Rectal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal midazolam (0.45 mg/kg)
Trial: 4156290
Drug: Potassium clorazepate
RxNorm normalized name: potassium clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium clorazepate (15 mg. at night)
Trial: 4156290
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg. t.d.s.)
Trial: 30785198
Drug: GEMOX (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX (gemcitabine 1000 mg/m2 on days 1 and 8, and oxaliplatin 100 mg/m2 on day 1)
Trial: 30785198
Drug: XELOX (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (capecitabine 1000 mg/m2, twice daily, on days 1‐14 and oxaliplatin 130 mg/m2 on day 1)
Trial: 29768118
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin)
Trial: 16938161
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G (General anaesthesia with propofol 2 mg kg‐1 and fentanyl 100 microg)
Trial: 16938161
Drug: Group S
RxNorm normalized name: Blood group substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S (Spinal anaesthesia with propofol infusion at 2 mg kg‐1 h‐1 after a 0.2 mg kg‐1 bolus dose and fentanyl 100 microg)
Trial: 16938161
Drug: Group T
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group T (TIVA with propofol 2 mg kg‐1 and fentanyl 100 microg)
Trial: 30997542
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel dressings
Trial: 28247679
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus Miramistin
Trial: 24684985
Drug: SD‐Ag and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD‐Ag and mupirocin (combination)
Trial: 24684985
Drug: SD‐Ag, mupirocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD‐Ag, mupirocin, and clotrimazole (combination)
Trial: 17533081
Drug: Multidisciplinary literature-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary literature-based approach to treatment
Trial: 16322283
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy with Premarin
Trial: 12081832
Drug: Folate supplement
RxNorm normalized name: Folate supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate supplement (400 microg/d)
Trial: 12081832
Drug: Exclusion diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusion diet (placebo daily)
Trial: 9459155
Drug: Tamoxifen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen alone (40 mg per day)
Trial: 9459155
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (40 mg of tamoxifen + 75 microg of CV 205-502 + 3 x 0.2 mg of octreotide)
Trial: 7871564
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of eicosapentanoic acid (EPA)
Trial: 7871564
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g of eicosapentanoic acid (EPA)
Trial: 7871564
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of corn oil (placebo)
Trial: 7871564
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g of corn oil (placebo)
Trial: 7871564
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fish oil (EPA)
Trial: 7871564
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fish oil (EPA)
Trial: 2371432
Drug: Routine follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine follow-up at 3 monthly intervals (follow-up group)
Trial: 7362785
Drug: No anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-hypertensive treatment (Control)
Trial: 23984100
Drug: 7.5% povidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% povidone iodine otic drops
Trial: 14988571
Drug: Anticoagulation (adjusted-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation (adjusted-dose warfarin)
Trial: 8890138
Drug: Amoxicillin (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (first choice antibiotic for AOM)
Trial: 19487582
Drug: All 4
RxNorm normalized name: Flex-All 454
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 4 classes of drug
Trial: 9380803
Drug: Chlorpromazine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (2.5 mg/l of dialysis solution)
Trial: 9380803
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (5 mg/l of dialysis solution)
Trial: 9380803
Drug: Isoprenaline hydrochloride
RxNorm normalized name: Isoprenaline hydrochloride
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline hydrochloride (0.5 mg/l of dialysis solution)
Trial: 9380803
Drug: 1.5 g%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g% glucose dialysis solution
Trial: 7871062
Drug: Melatonin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 80 mg
Trial: 30255400
Drug: Amiodarone (AMIO)
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone (AMIO) monotherapy (300 mg in 30 min + 1125 mg in 36 h iv)
Trial: 30255400
Drug: Amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone plus Ranolazine (AMIO + RAN) combination (500 mg po + 375 mg after 6 h and 375 mg twice daily thereafter)
Trial: 27496105
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion (0.1 μg/kg/min for 24 hours)
Trial: 24650009
Drug: Sotatercept (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (0.1, 0.3, or 0.5 mg/kg)
Trial: 22181973
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg letrozole/day for five days combined with intrauterine insemination
Trial: 22181973
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clomiphene citrate/day for five days combined with intrauterine insemination
Trial: 18853679
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg orally 60 minutes before surgery) and ketamine (20 mg intravenous bolus followed by intraoperative perfusion of 20 mg h(‐1))
Trial: 8688997
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg losigamone
Trial: 8688997
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg losigamone
Trial: 8688997
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg losigamone
Trial: 8688997
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg losigamone for 6 days (t.i.d.)
Trial: 8688997
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg losigamone for 28 days
Trial: 8688997
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg losigamone for 28 days
Trial: 8688997
Drug: 1,800 mg
RxNorm normalized name: daratumumab-hyaluronidase-fihj 1,800 mg-30,000 unit/15 mL SUBCUT VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 mg losigamone for 28 days
Trial: 6129370
Drug: hpGRF-40 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hpGRF-40 (1 microgram/kg bodyweight, administered as an intravenous bolus)
Trial: 30786861
Drug: 12-week moderate-intensity
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions.
Trial: 29042662
Drug: Continuing NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing NA therapy
Trial: 25099775
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RehaCom cognitive training and acupuncture
Trial: 22824097
Drug: DAS‐steered treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS‐steered treatment (DAS ≤ 2.4)
Trial: 15073704
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of milrinone
Trial: 15073704
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of milrinone and NO
Trial: 11835382
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (8g/m2)
Trial: 7997415
Drug: Prednisone 2
RxNorm normalized name: prednisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2 mg/kg/day reducing to zero over 14 days (n = 12)
Trial: 18325601
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (Group L)
Trial: 1729559
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with EMLA cream applied on one side of the scrotum.
Trial: 1729559
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with EMLA cream applied on one side of the scrotum before bilateral mepivacaine infiltration.
Trial: 6710300
Drug: 0.5 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 per cent chlorhexidine gluconate spray
Trial: 3088636
Drug: Binedaline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binedaline (50 mg)
Trial: 29300925
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (0.8 mg/kg/dose)
Trial: 19927151
Drug: Olmesartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20 mg day(-1))
Trial: 19927151
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg day(-1))
Trial: 16604818
Drug: IFNbeta‐1b‐G (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1b‐G (glucose formulation)
Trial: 16604818
Drug: IFNbeta‐1b‐M (refrigeration-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1b‐M (refrigeration-free formulation)
Trial: 8851595
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing (CD) vancomycin therapy (1 g every 12 h)
Trial: 8851595
Drug: Continuous-infusion (CI)
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion (CI) vancomycin therapy (500 mg loading dose followed by 2 g infused over 24 h)
Trial: 1496949
Drug: Somatotropin recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in six injections per week for 2 years
Trial: 1496949
Drug: Somatotropin recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in three injections per week for 2 years
Trial: 6149737
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) benztropine mesylate (2 mg)
Trial: 6149737
Drug: Oral benztropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral benztropine mesylate (2 mg three times a day)
Trial: 6149737
Drug: Neuroleptic withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic withdrawal (four weeks of dose tapering and six weeks of placebo treatment)
Trial: 30403937
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (ivermectin + diethylcarbamazine + albendazole)
Trial: 30403937
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (diethylcarbamazine + albendazole) - single dose
Trial: 30403937
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (diethylcarbamazine + albendazole) - administered once a year for 3 years
Trial: 26718094
Drug: Group Cognitive-Behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive-Behavioral Treatment (GCBT)
Trial: 25323538
Drug: Sunflower seed
RxNorm normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower seed oil (SSO) applied daily during the first 10 postnatal days
Trial: 20733134
Drug: Oral midostaurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral midostaurin at 50 or 100 mg twice daily
Trial: 20733134
Drug: Oral midostaurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral midostaurin at 100 mg twice daily
Trial: 20733134
Drug: Oral midostaurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral midostaurin at 50 mg twice daily
Trial: 11753159
Drug: Erythromycin 10
RxNorm normalized name: erythromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 10 mg/kg, 8 hourly for 7 days
Trial: 9848502
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein containing 1.39 mg isoflavones/g protein (ISP56)
Trial: 9848502
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein containing 2.25 mg isoflavones/g protein (ISP90)
Trial: 2754021
Drug: Felodipine treatment
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine treatment 10 mg b.i.d. for 8 weeks
Trial: 20121
Drug: Air injection
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air injection technique
Trial: 29525602
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg aflibercept
Trial: 22169831
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (3 J) and exercises
Trial: 19605849
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m² for 5 days intravenously, every 28 days, for 6 courses)
Trial: 19605849
Drug: Chlorambucil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (0.4 mg/kg body weight with an increase to 0.8 mg/kg, every 15 days, for 12 months)
Trial: 8980759
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally every 12 h for 45 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Trial: 8980759
Drug: Doxycycline at
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline at the same dosage for 30 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Trial: 8945276
Drug: Conventional disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional disposable syringes with multiple‐ and single‐dose vials
Trial: 2886245
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine at 9 PM only
Trial: 28809789
Drug: G-Breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Breakfast
Trial: 24681850
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) with adaptive statistical iterative reconstruction (ASIR) blending ratios (0%, 30%, 50%, and 70%)
Trial: 31277780
Drug: Standard-dose computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose computed tomography (SDCT)
Trial: 20921462
Drug: Panitumumab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab 6.0 mg/kg plus FOLFIRI
Trial: 18826749
Drug: Travoprost (a.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost (a.m. dosing)
Trial: 18826749
Drug: Latanoprost (a.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (a.m. dosing)
Trial: 18826749
Drug: Travoprost (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost (evening dosing)
Trial: 18826749
Drug: Latanoprost (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (evening dosing)
Trial: 14585918
Drug: Oral valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valdecoxib 20 mg once daily
Trial: 8614068
Drug: Sequential gradient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential gradient intermittent pneumatic compression (SGIPC)
Trial: 22321131
Drug: Harm reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harm reduction focused school drug education program (10 lessons in year eight and 8 lessons in year nine)